An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

Eli Lilly emerged as the perceived winner at the ADA conference after positive data on retatrutide and its weight-loss pill Foundayo, reinforcing RBC’s view that Lilly is widening its lead over Novo Nordisk. Lilly posted 56% revenue growth last quarter, while Novo Nordisk reported negative adjusted sales growth and guided to further declines, leaving the valuation gap wide at 30x forward earnings for Lilly versus 13.6x for Novo. The article is largely comparative and valuation-focused, with modest implications for the GLP-1 drug sector.

Analysis

The market is still treating GLP-1 as a winner-take-most category, but the more durable edge is shifting from “best molecule” to “best execution at scale.” Lilly’s advantage is now self-reinforcing: stronger growth supports premium valuation, which in turn expands its ability to fund combination studies, DTC spend, manufacturing, and physician education faster than peers. That creates a second-order moat in supply reliability and formulation breadth, not just clinical data.

Novo’s setup is more nuanced than the headline implies. The stock can stay structurally cheap if investors keep anchoring on near-term sales decay, but the asymmetric risk is that any credible re-acceleration in prescriptions or a cleaner late-stage readout on CagriSema forces a sharp multiple re-rating from depressed levels. The key point is timing: the market is rewarding visible quarterly acceleration, not pipeline optionality, so the burden of proof remains on NVO over the next 1-2 earnings cycles.

The competitive risk is also broader than LLY vs NVO. As obesity and diabetes treatments move into pills, combo therapies, and comorbidity-specific labeling, smaller competitors and late entrants face a “scale tax” in manufacturing, payer access, and adherence support. That should pressure PFE and other aspirants more than the article suggests, because the winning products will likely be those with the best real-world persistence, not the highest headline weight-loss efficacy.

Contrarian view: Lilly’s lead may be priced as if it is permanent, but premium GLP-1 expectations leave the stock vulnerable to any sign of slowing new-user growth, rebate pressure, or supply normalization. The cleaner trade is not to chase Lilly outright, but to own the spread between high-quality optionality and expensive certainty: NVO can outperform sharply on even modest operational stabilization, while LLY needs continued perfection to justify its premium.

Key Decisions for Investors

• Initiate a relative-value pair: long NVO / short LLY for a 3-6 month horizon, sized small-to-medium. Base case is valuation mean reversion if NVO prints even modest sequential prescription stabilization; risk is a continued growth-gap widening, so cap downside with a tight stop if LLY guides above-consensus again.
• If not already long, wait on LLY until the next quarterly print before adding. The stock screens as a quality compounder, but at ~30x forward earnings the risk/reward is poor unless revenue growth re-accelerates into the next two quarters; upside is limited, downside on any miss is meaningful.
• Buy NVO call spreads 3-6 months out rather than stock if you want convexity on a turnaround. The setup is favorable because the equity is pricing in a prolonged growth trough; a small improvement in sales trajectory could drive a disproportionate multiple expansion.
• Fade smaller GLP-1 aspirants and adjacent pharma laggards on rallies, especially PFE, over the next 1-2 quarters. The category is consolidating around scale leaders, and weaker players face a rising cost of entry in manufacturing, access, and post-launch support.
• Set a catalyst watch on the next two earnings cycles: if NVO shows sequential prescription growth or better-than-feared guidance, rotate quickly into the laggard. If LLY shows any deceleration in new-starts or tighter gross-to-net, use that as a trigger to trim exposure or add to the pair trade.